Hemopathy Clinical Trial
Official title:
Sequential Analysis in Patients With an Hemopathy
Recent advances in hematology clearly illustrate that the simple "clonal" nature of various
hematological malignancies may not really reflect the reality of malignant cells natural
expansion. This has been nicely illustrated in recent works in AML for example where
subclones coexists in the same patient at the same time, but could also differentially expand
over time because of effects of therapeutics intervention, but also by oncogenic spontaneous
events (1).
These observations have been done recently because of next generation sequencing that allows
to discriminate in the same tumor samples, different subclones and to analyse the clonal
architecture. Sequential analyses could help us to identify the first oncogenic event and to
correlate disease progression to the emergence of subclones.
For all these reasons it is of a major interest to precisely understand the architecture of
the clone in MPNs, especially to understand which is the initiating event and how from this
initial event the clone develops.
In MPNs in which JAK2V617F is the initiating event, its targeting is expected to be extremely
effective. If JAK2V617F is a secondary event its targeting might allow to alleviate the MPN,
but may favor the development of other malignant hemopathies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02751112 -
Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease
|
N/A | |
| Completed |
NCT02065297 -
Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
|
||
| Recruiting |
NCT03102905 -
Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
|
N/A | |
| Not yet recruiting |
NCT06369389 -
Real-life Management of Patients Eligible for CAR-T Cell Therapy
|